首页> 外文期刊>Expert opinion on biological therapy >Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.
【24h】

Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.

机译:细胞毒性三联体再加上生物制剂:可最大程度地提高转移性​​结直肠癌的前期治疗潜力的最新技术。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION: Up-front treatment of metastatic colorectal cancer (mCRC) has progressively become more complex during last few years. Nowadays, treatment options range from monotherapies with biologics or traditional chemotherapeutic agents to intensive combinations of chemotherapy plus targeted drugs. AREAS COVERED: This review deals with the results of the most recent first-line trials in the medical treatment of mCRC, with a special focus on recently closed or ongoing trials of intensive concomitant combinations of all active cytotoxics plus a biologic agent. EXPERT OPINION: Combinations of three cytotoxic drugs plus a biologic are under clinical investigation and therefore should not be recommended for routine use, nevertheless preliminary results are promising. The main challenges for the future are not only to demonstrate the real clinical usefulness of intensive approaches, but also to gain the ability of defining prior to treatment which patients will benefit most on the basis of clinical and molecular elements.
机译:简介:在过去的几年中,转移性结直肠癌(mCRC)的前期治疗已逐渐变得更加复杂。如今,治疗选择范围从单一疗法与生物制剂或传统的化学治疗药,到化学疗法与靶向药物的强效组合。覆盖的领域:本综述涉及mCRC药物治疗的最新一线试验的结果,特别关注所有活性细胞毒物加生物制剂的密集伴随组合的近期封闭或正在进行的试验。专家意见:三种细胞毒性药物与生物制剂的组合正在临床研究中,因此不建议常规使用,尽管初步结果令人鼓舞。未来的主要挑战不仅在于证明强化治疗的真正临床实用性,而且在于获得在治疗前确定哪些患者将在临床和分子基础上受益最大的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号